In the phase 3 ACTG A5359 LATITUDE trial, investigators evaluated whether monthly, long-acting injectable cabotegravir plus rilpivirine could reduce regimen failure compared with standard oral...
In a large multicountry trial, researchers evaluated whether an integrase inhibitor–based regimen offers comparable or superior treatment outcomes to a boosted protease inhibitor regimen in adults with...
A national analysis presented at the 2025 AHA Scientific Sessions found that patients with HIV hospitalized with cardiac implantable electronic device–related infective endocarditis had significantly lower...
A new longitudinal study published in the Journal of the American Academy of Dermatology evaluated more than a decade of data from adults living with HIV, revealing a steady decline in dermatologic disease...
A pilot randomized trial found that offering immediate pre-exposure prophylaxis (PrEP) initiation with a 28-day starter pack in the emergency department did not improve PrEP use or retention compared with...
Managing HIV today means balancing speed, precision, and prevention. From deciding when to start antiretroviral therapy (ART) to optimizing follow-up labs and ensuring vaccine and prophylaxis coverage,...
Results from a phase 2B randomized, double-blind, placebo-controlled trial suggest that semaglutide not only reduces inflammation and adiposity in people with HIV but may also provide a neurocognitive...
Excess visceral fat, rather than BMI alone, is a key driver of cardiovascular risk in people with HIV receiving antiretroviral therapy. The study authors presented their findings at the Conference on...
